NKTR-255 is a polymer-conjugated IL-15 with unique mechanisms of action on T and natural killer cells
Tanya O. Robinson(University of Mississippi Medical Center), Kimberly S. Schluns(Loyola University Chicago), Takahiro Miyazaki(Nektar Therapeutics (United States)), Jonathan Zalevsky(Nektar Therapeutics (United States)), Allison Chang(Rice University), Achintyan Gangadharan(The University of Texas MD Anderson Cancer Center), Shweta Hegde(The University of Texas MD Anderson Cancer Center), Loui Madakamutil(Nektar Therapeutics (United States)), Sarai Rivas(The University of Texas MD Anderson Cancer Center)
Cited by 25
Related Papers
β-Arrestin–Dependent Endocytosis of Proteinase-Activated Receptor 2 Is Required for Intracellular Targeting of Activated Erk1/2
|The Journal of Cell Biology|2000|816
Enhanced antibody half-life improves in vivo activity
|Nature Biotechnology|2010|654
JNK and Tumor Necrosis Factor-α Mediate Free Fatty Acid-induced Insulin Resistance in 3T3-L1 Adipocytes
|Journal of Biological Chemistry|2005|403